Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Inclusion Criteria: Written informed consent must be obtained prior to any screening procedures. Patients must meet all Inclusion Criteria: * Patient is able to communicate well with the investigator, to understand and comply with the requirements of the study. * Patients must be 18 years of age or older; elderly patients must be fit to receive intensive induction and consolidation chemotherapy * Patients must have a documented FLT3 mutation (ITD or TKD) * Patients must have an ECOG Performance Status of ≤ 2 * Patients must have a documented unequivocal diagnosis of AML according to WHO 2008 classification (\>20% blasts in the bone marrow and/or peripheral blood), excluding M3 (acute promyelocytic leukemia). * Patients requiring intrathecal chemotherapy must have a minimum washout of 48 hours prior to the first dose of midostaurin * AML patients with a history of antecedent treatment for myelodysplasia (MDS), e.g. azacitidine or decitabine, remain eligible for treatment on this study. These agents must have been discontinued for a period of at least 30 days or 5 half-lives of the drug (whichever is greater) before midostaurin can be administered. * Secondary AML, e.g. patients with antecedent history of treatment for prior malignancy Patients must have the following laboratory values (Direct Bilirubin ≤ 2.5 x ULN, Serum Creatinine ≤ 2.5 x ULN) Exclusion Criteria: Patients eligible for this study must not meet any of the following criteria: * Prior therapy for AML with the following exceptions: (emergency leukapheresis, emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days, cranial RT for CNS leukostasis (one dose only), growth factor/cytokine support) * Patients with LVEF less than 45% (by echocardiogram or MUGA) or symptomatic congestive heart failure, Class III or IV according to New York Heart Association (NYHA) classification * Patients with any uncontrolled illness, including, but not limited to, acute or chronic pancreatitis or uncontrolled infection * QTc \>500 msec on screening ECG. History of hypersensitivity to any drugs or metabolites of similar chemical classes as the IMP. * Participation in a prior investigational interventional (drug) study with administration of the investigational product within 30 days or 5 half-lives of the investigational product, whichever is longer. * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. * Sexually active males should not father a child during this study and for upto 5 months following.